| Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial IFNB Multiple Sclerosis Study Group Neurology 43 (4), 655-655, 1993 | 2820 | 1993 |
| Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS) DW Langdon, MP Amato, J Boringa, B Brochet, F Foley, S Fredrikson, ... Multiple Sclerosis Journal 18 (6), 891-898, 2012 | 919 | 2012 |
| Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, AT Reder, ... The Lancet Neurology 13 (6), 545-556, 2014 | 899 | 2014 |
| Interferon beta‐lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial IFNB Multiple Sclerosis Study Group and the University of British Columbia ... Neurology 45 (7), 1277-1285, 1995 | 595 | 1995 |
| Validation of the functional assessment of multiple sclerosis quality of life instrument DF Cella, K Dineen, B Arnason, A Reder, KA Webster, G Karabatsos, ... Neurology 47 (1), 129-139, 1996 | 592 | 1996 |
| Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology D Cella, JS Lai, CJ Nowinski, D Victorson, A Peterman, D Miller, ... Neurology 78 (23), 1860-1867, 2012 | 577 | 2012 |
| Vitamin D and multiple sclerosis: a comprehensive review MB Sintzel, M Rametta, AT Reder Neurology and therapy 7, 59-85, 2018 | 434 | 2018 |
| Brief International Cognitive Assessment for MS (BICAMS): international standards for validation RHB Benedict, MP Amato, J Boringa, B Brochet, F Foley, S Fredrikson, ... BMC neurology 12, 1-7, 2012 | 428 | 2012 |
| Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis D Maimone, S Gregory, BGW Arnason, AT Reder Journal of neuroimmunology 32 (1), 67-74, 1991 | 401 | 1991 |
| Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011 | 360 | 2011 |
| Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial DS Goodin, AT Reder, GC Ebers, G Cutter, M Kremenchutzky, J Oger, ... Neurology 78 (17), 1315-1322, 2012 | 310 | 2012 |
| Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis R Zivadinov, AT Reder, M Filippi, A Minagar, O Stuve, H Lassmann, ... Neurology 71 (2), 136-144, 2008 | 300 | 2008 |
| Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis CH Polman, A Bertolotto, F Deisenhammer, G Giovannoni, HP Hartung, ... The Lancet Neurology 9 (7), 740-750, 2010 | 271 | 2010 |
| Increased CD80 (+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. K Genc, DL Dona, AT Reder The Journal of clinical investigation 99 (11), 2664-2671, 1997 | 262 | 1997 |
| Neuroleukin: a lymphokine product of lectin-stimulated T cells ME Gurney, BR Apatoff, GT Spear, MJ Baumel, JP Antel, MB Bania, ... Science 234 (4776), 574-581, 1986 | 246 | 1986 |
| Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis B Banwell, AT Reder, L Krupp, S Tenembaum, M Eraksoy, B Alexey, ... Neurology 66 (4), 472-476, 2006 | 237 | 2006 |
| Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report:[RETIRED] Report of the Therapeutics and Technology … DS Goodin, EM Frohman, B Hurwitz, PW O’Connor, JJ Oger, AT Reder, ... Neurology 68 (13), 977-984, 2007 | 231 | 2007 |
| Immunology of multiple sclerosis AT Reder, BGW Arnason Hand¬book of Clinical Neurology; Demyelinating Diseases, PJ Vinken, GW Bruyn …, 1985 | 230* | 1985 |
| Cytokines in the vitreous of patients with proliferative diabetic retinopathy AMA El Asrar, D Maimone, PH Morse, S Gregory, AT Reder American journal of ophthalmology 114 (6), 731-736, 1992 | 228 | 1992 |
| Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial RR Voskuhl, HJ Wang, TCJ Wu, NL Sicotte, K Nakamura, F Kurth, N Itoh, ... The Lancet Neurology 15 (1), 35-46, 2016 | 212 | 2016 |
David K. B. LiUniversity of British ColumbiaVerified email at ubc.ca
